Clare McGrane

Recent coverage

Front-page news, podcasts and videos about Clare

See all 4

AdaptX (formerly MDMetrix) raises $6M Series A led by Vulcan Capital to expand AI-driven healthcare data platform

AdaptX, formerly MDMetrix, raised $6 million in a Series A led by Vulcan Capital to expand its AI-driven platform that extracts insights from electronic medical records to improve clinical, financial and equity outcomes. The Seattle startup, founded by anesthesiologist Dr. Dan Low, has raised over $11 million total, employs about 20 people, and will use proceeds for hiring and product development.

MDMetrix and TransformativeMed Offer Free COVID-19 Tracking Tools to Hospitals; Deployed at UW Medicine

Two Seattle startups, MDMetrix and TransformativeMed, are offering their combined COVID-19 patient-tracking and analysis tools free to hospitals so clinicians can spot treatment and spread trends across patient groups. Their systems are already in use at University of Washington Medicine to screen patients, track symptoms and labs, and report data to state health departments.

Seattle Children’s spin-out MDMetrix raises $3M seed round led by Founders’ Co-op to mine EMR data

MDMetrix, a Seattle Children’s spin-out founded by Dr. Dan Low, raised $3 million in a seed round led by Founders’ Co-op to make electronic medical records more useful for clinicians. CEO Warren Ratliff says the funds will accelerate product development and apply AI to help caregivers extract actionable insights and track clinical improvements over time.

By Clare

See all 76

Biomatics Capital raises $300M fund, hires Gates Foundation global health director Mike Poole to lead neurology investments

Biomatics Capital raised a $300 million second fund to invest in 15–20 healthcare and life-sciences startups focused on innovations at the intersection of healthcare and technology, and added two partners — Dr. Mike Poole from the Bill & Melinda Gates Foundation to lead neurology-focused, data- and genomics-enabled investments, and biotech investor Errik Anderson.

SEngine Precision Medicine raises $3M (round now $8.2M), adds Nobel laureate Lee Hartwell and investor Elliott Burkland to board

SEngine Precision Medicine raised $3 million, bringing its current round to $8.2 million, and appointed former Fred Hutch president and Nobel laureate Dr. Lee Hartwell to its board; new investor Elliott Burkland of Bangarang Group will also join the board. The company uses its PARIS test to grow patients’ tumor cells as organoids and analyze drug combinations to personalize cancer treatment.

Online